A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.57 USD -5.38% Market Closed
Market Cap: 416.1m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Aquestive Therapeutics Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Operating Expenses Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Operating Expenses
-$55.2m
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Expenses
-$36.5B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Expenses
-$24.9B
CAGR 3-Years
2%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Pfizer Inc
NYSE:PFE
Operating Expenses
-$29.4B
CAGR 3-Years
-11%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Expenses
-$26.7B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Eli Lilly and Co
NYSE:LLY
Operating Expenses
-$18.6B
CAGR 3-Years
-12%
CAGR 5-Years
-10%
CAGR 10-Years
-5%

See Also

What is Aquestive Therapeutics Inc's Operating Expenses?
Operating Expenses
-55.2m USD

Based on the financial report for Jun 30, 2024, Aquestive Therapeutics Inc's Operating Expenses amounts to -55.2m USD.

What is Aquestive Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
9%

Over the last year, the Operating Expenses growth was -3%. The average annual Operating Expenses growth rates for Aquestive Therapeutics Inc have been 9% over the past three years , 9% over the past five years .

Back to Top